130 related articles for article (PubMed ID: 12450788)
1. The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?
Sellers WR; Loda M
Cancer Cell; 2002 Nov; 2(5):349-50. PubMed ID: 12450788
[TBL] [Abstract][Full Text] [Related]
2. The polycomb group protein EZH2 is involved in progression of prostate cancer.
Varambally S; Dhanasekaran SM; Zhou M; Barrette TR; Kumar-Sinha C; Sanda MG; Ghosh D; Pienta KJ; Sewalt RG; Otte AP; Rubin MA; Chinnaiyan AM
Nature; 2002 Oct; 419(6907):624-9. PubMed ID: 12374981
[TBL] [Abstract][Full Text] [Related]
3. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
4. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
Zeidler M; Kleer CG
J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786
[TBL] [Abstract][Full Text] [Related]
5. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
6. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation.
Kuzmichev A; Margueron R; Vaquero A; Preissner TS; Scher M; Kirmizis A; Ouyang X; Brockdorff N; Abate-Shen C; Farnham P; Reinberg D
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1859-64. PubMed ID: 15684044
[TBL] [Abstract][Full Text] [Related]
7. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
Cho KS; Oh HY; Lee EJ; Hong SJ
Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
[TBL] [Abstract][Full Text] [Related]
8. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
9. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
10. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M
Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462
[TBL] [Abstract][Full Text] [Related]
11. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
Hwang C; Giri VN; Wilkinson JC; Wright CW; Wilkinson AS; Cooney KA; Duckett CS
Breast Cancer Res Treat; 2008 Jan; 107(2):235-42. PubMed ID: 17453341
[TBL] [Abstract][Full Text] [Related]
12. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
13. EZH2 and cancer stem cells: fact or fiction?
Crea F
Epigenomics; 2011 Apr; 3(2):127-8. PubMed ID: 22122274
[No Abstract] [Full Text] [Related]
14. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.
Yu J; Cao Q; Yu J; Wu L; Dallol A; Li J; Chen G; Grasso C; Cao X; Lonigro RJ; Varambally S; Mehra R; Palanisamy N; Wu JY; Latif F; Chinnaiyan AM
Oncogene; 2010 Sep; 29(39):5370-80. PubMed ID: 20622896
[TBL] [Abstract][Full Text] [Related]
15. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements.
Tonini T; D'Andrilli G; Fucito A; Gaspa L; Bagella L
J Cell Physiol; 2008 Feb; 214(2):295-300. PubMed ID: 17786943
[TBL] [Abstract][Full Text] [Related]
16. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract][Full Text] [Related]
17. The transcriptional repression by NIPP1 is mediated by Polycomb group proteins.
Roy N; Van Eynde A; Beke L; Nuytten M; Bollen M
Biochim Biophys Acta; 2007; 1769(9-10):541-5. PubMed ID: 17804093
[TBL] [Abstract][Full Text] [Related]
18. Quantitative multi-gene expression profiling of primary prostate cancer.
Schmidt U; Fuessel S; Koch R; Baretton GB; Lohse A; Tomasetti S; Unversucht S; Froehner M; Wirth MP; Meye A
Prostate; 2006 Oct; 66(14):1521-34. PubMed ID: 16921506
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between Polycomb and androgen receptor during oncogenic transformation.
Zhao JC; Yu J; Runkle C; Wu L; Hu M; Wu D; Liu JS; Wang Q; Qin ZS; Yu J
Genome Res; 2012 Feb; 22(2):322-31. PubMed ID: 22179855
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]